Mundipharma announces the positive outcome of the European Decentralised Procedure (DCP) for flutiform® k-haler®, a novel treatment for adolescents and adults with asthma

CHMP positive opinion for opioid dependence treatment with Zubsolv®(buprenorphine and naloxone) in Europe

Mundipharma receives CHMP positive opinion for Nyxoid®(intranasal naloxone spray)

Largest ever flutiform®study confirms effectiveness and tolerability in real-world clinical practice: Findings from AffIRM study to be presented at ERS 2017

New data presented at ERS 2017 on flutiform® k-haler® (fluticasone propionate and formoterol), Mundipharma’s novel breath-triggered aerosol inhaler

Mundipharma announces exclusive distribution agreement with Janssen for two primary care diabetes treatments Invokana®(canagliflozin) and Vokanamet®(canagliflozin /metformin) for selected European countries

Mundipharma and CellAct announce new deal for the worldwide development and commercialization of smart chemotherapy CAP7.1

New data show Truxima®(CT-P10) to have comparable efficacy and tolerability in advanced follicular lymphoma to reference i.v. rituximab